In addition, this regimen is FDA-approved for use in combination with docetaxel for HER2-positive metastatic breast cancer, or in combination with chemotherapy for adjuvant and neoadjuvant therapies for HER2-positive locally advanced, inflammatory, or early-stage breast cancer [5–7]. The gene discussed is ERBB2; the disease is breast cancer.